Robert Zielinski - Concepedia

Author

Robert Zielinski

Also Known As

Ian Vela, J M Zielinski, R L Kodell, D Krewski, R R Zielinski, R Zielinski, R. Zielinski, R., Zielinski, Rob Zielinski, Robert R Zielinski, Robert R. Zielinski, Robert Richard Zielinski

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

The University of Sydney Peter MacCallum Cancer Centre Western Sydney University Monash Health Monash University

About

Robert Zielinski is an author at The University of Sydney specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	8	527
2	Engineering	1	1	39
3	Health Sciences	1	1	33
4	Natural Sciences	1	1	39
5	Biology	1	1	39

Robert Zielinski

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineClinical Trials	2023	175
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP Martin R. Stockler, Andrew Martin, Ian D. Davis, Journal of Clinical Oncology	2021	57
Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). Ian D. Davis, Andrew Martin, Robert Zielinski, Journal of Clinical Oncology Overall Survival OutcomesClinical EndpointPrognosisPharmacotherapyLogistic Analysis	2022	52
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy Christopher J. Sweeney, Andrew Martin, Martin R. Stockler, European Urology UrologyOncologyGenitourinary CancerMedicineAndrogen Deprivation Therapy	2021	48
Seasonal and diurnal activity of sixgill sharks (<i>Hexanchus griseus</i>) on a shallow water reef in the Strait of Georgia, British Columbia Robert L. Dunbrack, Robert Zielinski Canadian Journal of Zoology BiologyBenthic CommunityEngineeringShallow Water ReefBluntnose Sixgill Shark	2003	39
Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy? Michael S. Sabel, Ellis Levine, Thelma C. Hurd, American Journal of Clinical Oncology Surgical OncologyHeart FailureBreast OncologyPharmacotherapyMetronomic Chemotherapy	2001	33
Consensus minimum data set for lung cancer multidisciplinary teams: Results of a Delphi process Emily Stone, Nicole Rankin, Jane Phillips, Respirology	2018	29
Custirsen (OGX-011): A Second-Generation Antisense Inhibitor of Clusterin in Development for the Treatment of Prostate Cancer Robert Zielinski, Kim N. Future Oncology Novel TherapyMedicineBroad-spectrum Treatment ResistancePharmacologySecond-generation Antisense Inhibitor	2012	24
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) Nizar M. Tannir, Maria Nirvana Formiga, Konstantin Penkov, Journal of Clinical Oncology	2024	22

Page 1